Europe

Roche gets European approval for Tecentriq combo vs. lung cancer
Roche gets European approval for Tecentriq combo vs. lung cancer
Reuters
Roche
Europe
Tecentriq
Avastin
lung cancer
metastatic non-squamous non-small cell lung cancer
Flag link:
AbbVie, Akcea benefit from latest CHMP recommendations
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Europe
CHMP
AbbVie
Akcea
Biomarin
Sanofi
Pfizer
drug approvals
Flag link:
Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
Endpoints
Pfizer
Europe
JAK inhibitors
Xeljanz
Flag link:
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Endpoints
Shionogi
Europe
opioid-induced constipation
Symproic
Rizmoic
Flag link:
Brexit could disrupt medicine supplies for six months – minister
Brexit could disrupt medicine supplies for six months – minister
Pharmaforum
Brexit
UK
Europe
Flag link:
Brexit Likely to Cause Talent Shortage for Biopharma in the UK
Brexit Likely to Cause Talent Shortage for Biopharma in the UK
BioSpace
UK
Europe
Brexit
Flag link:
U.K. Could Be Kicked Out Of Newly Launched Pharma Tech Security System Because Of Brexit
U.K. Could Be Kicked Out Of Newly Launched Pharma Tech Security System Because Of Brexit
Forbes
Europe
UK
Brexit
Falsified Medicines Directive
security
Flag link:
AZ’s lung drug gets fast development in EU and US
AZ’s lung drug gets fast development in EU and US
Pharmaforum
AstraZeneca
MEDI8897
RSV
Europe
fast track
Flag link:
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Pharmaforum
CAR-T
CAR-T Congress
oncology
Novartis
Kymriah
Europe
Flag link:
Brexit could hinder CAR-T reimbursement in Europe
Brexit could hinder CAR-T reimbursement in Europe
Pharmaforum
Brexit
UK
Europe
CAR-T
Flag link:
Estonia Houses The Biggest Biobank In Europe
Estonia Houses The Biggest Biobank In Europe
Forbes
Europe
biotech
Estonia
biobank
Flag link:
Biopharma Companies Explain Brexit Preparations
Biopharma Companies Explain Brexit Preparations
RAPS.org
Brexit
UK
Europe
drug shortages
Flag link:
Novartis urges Britain to secure drug supplies before Brexit
Novartis urges Britain to secure drug supplies before Brexit
Yahoo/Reuters
Novartis
UK
Brexit
Europe
drug shortages
Flag link:
25 European medtech and life sciences start-ups to watch in 2019
25 European medtech and life sciences start-ups to watch in 2019
Silicon Republic
Europe
devices
startups
ADA
Ava
Aiforia
Bambi Medical
BioBeats
BrainWave Bank
Diaceutics
Dobco Medical Systems
Doctena
Etsimo
Fluidic Analytics
Heartbeat Medical
HealthBeacon
Healthera
Healx
Kite Medical
Medherant
Neurent Medical
Nuritas
Oura
Sword Health
UgenTec
WhiteSwell
Ultromics
Xeltis
Flag link:
The Biotech VC View: What Does 2019 Hold For European Health Startups?
The Biotech VC View: What Does 2019 Hold For European Health Startups?
Forbes
Europe
biotech
venture capital
Flag link:
Brexit and beyond: the challenges ahead for pharma
Brexit and beyond: the challenges ahead for pharma
Pharmaforum
Brexit
UK
Europe
Flag link:
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
CP Wire
Janssen
JNJ
Erleada
prostate cancer
Europe
Flag link:
As Brexit nears, EMA improves staff retention forecast, commits to uninterrupted drug evaluations
As Brexit nears, EMA improves staff retention forecast, commits to uninterrupted drug evaluations
Fierce Biotech
EMA
Europe
Brexit
UK
Amsterdam
Flag link:
US loses, EU wins as Chinese biotech investment shifts focus
US loses, EU wins as Chinese biotech investment shifts focus
Pharmaforum
China
Europe
biotech
Flag link:
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs
KHN
biologics
United States
Europe
Flag link:

Pages